Assessing the Limits: Enhancing Patient Management with Highly Sensitive HIV Immunoassays
Date: Thursday, December 5, 2024
Time: 11:00 AM ET / 10:00 AM CT / 8:00 AM PT
Duration: 1 Hour
Already registered? Click here to log in.
Summary
Join Dr Rafał Wlazeł as we have a conversation on the critical role of immunoassays in HIV diagnostics, emphasizing the importance of assay sensitivity and specificity. Participants will learn key considerations when evaluating HIV immunoassays and how highly sensitive assays improve diagnostic accuracy, leading to more informed decisions. Additionally, emerging trends in HIV testing technologies will be explored.
Speakers
Rafał Wlazeł
Head of the Laboratory Diagnostics and Clinical Biochemistry Department
Medical University of Lodz, Poland
PhD MSc Rafal Nikodem Wlazel graduated from Laboratory Diagnostics Medical Faculty, Medical University of Lodz. Since 2009, he has specialized in laboratory medicine. He has served as a Senior Assistant and quality assurance assistant in the Central Medical Laboratory - the core lab of the Central Clinical Hospital of the Medical University of Lodz. Dr Wlazel has also served as an Assistant Professor and head of the Department of Laboratory Medicine and Clinical Biochemistry at the Medical University of Lodz. His scientific interests include laboratory biomarkers, analytical quality assurance, and assay performance characteristics. He works in cooperation with the National Centre for Quality Assessment in Laboratory Diagnostics. He is also the Author of The Guidelines from the Polish Society for Laboratory Diagnostics and the Diagnosis of the HIV Infection 2024.
Dr Ephraim Tsalik | Moderator
VP and Chief Scientific Officer for Infectious Disease, Danaher Diagnostics
Interim Chief Medical Officer, Cepheid
Ephraim Tsalik joined Danaher in 2022 as the VP and Chief Scientific Officer for Infectious Disease and is also the interim Chief Medical Officer at Cepheid, a Danaher company. Dr Tsalik obtained his MD/PhD from Columbia University followed by clinical training in Internal Medicine and Infectious Diseases at Duke University. As faculty at Duke through 2022, Dr. Tsalik studied host response biomarkers for infectious disease. He has been a member of the Antibacterial Resistance Leadership Group since 2014, having served as the Associate Director of the Laboratory Center. He is a Fellow of the IDSA, remains clinically active at the Durham VA Health Care System, and maintains an adjunct appointment with Duke University.
